Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.[7][8][9]
In April 2021, Valneva COVID-19 vaccine commenced phase III trials with approximately 4,000 participants.[14] In August 2021, New Zealand was chosen for trialing on 300 adult volunteers, due to low case numbers and slow vaccine rollout.[15] Positive results for the phase III trials were reported in October 2021.[16]
In May 2022, the company announced that Valneva COVID-19 vaccine was granted emergency use authorization from the United Arab Emirates (UAE).[17]
European Union
In May 2022, the European Union's drug regulator, the European Medicines Agency (EMA), accepted Valneva's filing of a marketing authorization for Valneva COVID-19 vaccine.[18]
In June 2022, the EMA announced that it would propose to authorize COVID-19 Vaccine (inactivated, adjuvanted) Valneva in the EU, primarily for vaccination of people aged 18 to 50 years.[19][20] It was approved for medical use in the European Union in June 2022.[2]
Economics
In September 2020, Valneva reached an agreement with Dynavax to help manufacture up to 100 million doses of vaccine in 2021 at its facility in Livingston, Scotland, and to provide up to 190 million doses over a 5-year period to the UK government.[21] Due to government support, Valneva progressed immediately into Phase III trials and develop production capacity before the full evaluation of the Phase I/II trial, rather than the traditional slower sequential approach which has lower financial risk.[22]
In September 2021, Valneva announced that the UK government had cancelled the vaccine order.[23] The cancellation reason was not officially given, but seems to be related to difficulties getting building materials due to Brexit[24] and not vaccine quality.
In November 2021, the European Commission approved a contract with Valneva providing the possibility to purchase almost 27 million doses of its vaccine in 2022. This also includes the possibility to adapt the vaccine to new variants as well as the order of an additional 33 million vaccine doses in 2023.[25]
Valneva COVID-19 vaccine was granted a marketing authorization in the European Union in June 2022.[2] In October 2023, the authorization was withdrawn for commercial reasons at the request Valneva Austria GmbH.[26]
References
^ ab"VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Archived from the original on 13 January 2021. Retrieved 11 January 2021.
^Clinical trial number NCT04671017 for "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults" at ClinicalTrials.gov
Clinical trial number NCT04671017 for "Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects" at ClinicalTrials.gov
Clinical trial number NCT04864561 for "Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE)" at ClinicalTrials.gov
Clinical trial number NCT04956224 for "Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years " at ClinicalTrials.gov
.svg){kind=small}
